United Kingdom
The Netherlands, Switzerland, Austria, Italy, Sweden, Denmark, France, Poland
Israel, Greece

Other events

ASM MICROBE conference 2016 in Boston
The ASM MICROBE conference (former ASM Annual Meeting + ICAAC) took place on June 18-21 in Boston. Mical Paul gave two presentations:
Colistin monotherapy is still a viable option for treatment of MDE-GNB
Controversies in antimicrobial stewardship

background logo AIDA-fine line

Model-informed Drug Development in Infectious Diseases
This face-to-face course introduces the principles of model-informed drug development, especially the development and application of pharmacokinetic-pharmacodynamic models for bacterial infections, tuberculosis, HIV, hepatitis, malaria and leishmaniasis. It will be presented by our AIDA partner the Pharmacometric Research Group, Department of Pharmaceutical Biosciences at Uppsala University, Sweden, together with the Institute of Pharmacy, Freie Universitaet Berlin, Germany.
The course takes place  on 8-12 February 2016, at the Biomedical Center, Husargatan, Uppsala, Sweden and is free of charge.

background logo AIDA-fine line

Postgraduate Education Course
The Postgraduate Education Course Improving the Dosage of Old Antibiotics has been organised by Johan Mouton and Ursula Theuretzbacher and takes place in Warsaw, Poland on 19-21 November 2015.

background logo AIDA-fine line

Meeting of the Transatlantic Task Force on Antimicrobial Resistance (TATFAR)
Let’s Keep Antibiotics Effective!
Luxembourg City, Luxembourg, October 22-23 2015
U. Theuretzbacher: Let’s keep new antibiotics effective by optimising the use of old drugs.

background logo AIDA-fine line

Bio2Device Meeting
U. Theuretzbacher: Redeveloping Old Antibiotics for Use: European Initiative
Oct 6th, 2015, Sunnyvale, CA, USA

background logo AIDA-fine line

2015 ACCP Annual Meeting
27-29 September, San Francisco, CA, USA

Symposium 1: Reviving old antibiotics: Applying new PK/PD strategies
U. Theuretzbacher: How Do You “Re-develop” an Old Antibiotic? Experience from the Publicly Funded Multinational Project AIDA

background logo AIDA-fine line

2nd International Conference on Polymyxins
Since the 1st International Conference on Polymyxins in 2013 (Prato, Italy), significant progress has been made in the clinical use and pharmacology of polymyxins, in particular PK/PD/TD and nephrotoxicity, and discovery of novel polymyxin-like antibiotics. The conference program featured cutting-edge presentations on a range of key topics.
Organizing committee:
Jian Li, Australia (Chair); Keith Kaye, USA (Deputy Chair); Robert Bonomo, USA; Otto Cars, Sweden; William Couet, France; Mike Dudley, USA; Johan Mouton, Netherlands; Roger Nation, Australia; David Paterson, Australia; Jason Pogue, USA; Vincent Tam, USA; Ursula Theuretzbacher, Austria; Brian Tsuji, USA; Paul Tulkens, Belgium; John Turnidge, Australia; Tony Velkov, Australia; Alexandre Zavascki, Brazil

background logo AIDA-fine line

ESCMID conference
Conference website

U. Theuretzbacher: How do you "re-develop" an old antibiotic: experience from AIDA

background logo AIDA-fine line

ICAAC 2014
The 54th ICAAC will take place in Washington DC, USA, Sept. 5-9, 2014
Partners of AIDA will present at this meeting:
- Johan Mouton:
  o PK/PD workshop
  o Pharmacodynamic Interaction Between Cefepime and Tazobactam in a Neutropenic Mouse Thigh Model
 o  Time-Kill Kinetics of Antibiotics Active Against Rapidly Growing Mycobacteria
- Stephan Harbarth:
  o Antimicrobial Stewardship in Hospitals workshop
  o Patients in ICUs Should Be Treated Routinely with Chlorhexidine Bathing and Intranasal Mupirocin (REDUCE MRSA Study): Con
  o Randomized Non-Inferiority Trial to Compare Trimethoprim-Sulfamethoxazole (TMP-SMX) plus Rifampicin versus Linezolid
     in the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Infection
  o Epidemiology of Staphylococcus aureus (SA) Surgical Site Infection (SSI) in Switzerland
- Alasdair MacGowan:
  o PK/PD workshop
  o Early Warning Score: A Marker of Severity and Prognosis in Patients with Gram-negative Bacteremia and Sepsis
  o Pharmacodynamics of Amikacin Against Aerobic Gram-Negative Rods Studied in an In Vitro Model of Infection
  o Pharmacodynamics of Ceftolozane/Tazobactam Against P.aeruginosa (PSA) Studied in an In Vitro Pharmacokinetic Model of Infection
  o Pharmacodynamics of Minocycline Against Acinetobacter baumannii Studied in a Pharmacokinetic Model of Infection
     Beta-Lactam Beta-Lactamase Inhibitor Combination Products
- Ursula Theuretzbacher:
  o PK/PD workshop
- Niels Frimodt-Moller
  o Fosfomycin PK/PD in Experimental Urinary Tract Infection (UTI)
  o No Clear Correlation Between Ciprofloxacin (cip) Treatment Effect And Cip-resistance In E. Coli In Experimental Urinary Tract Infection (uti)
  o Resistance to mecillinam in Escherichia coli during treatment
  o Risk Factors Associated with ESBL-producing E.coli (ESBL) UTI in General Practices (GP), as Related to UTI Caused by Resistant E.coli (Non-ESBL),
     or Fully Susceptible E.coli, Respectively
- Yehuda Carmeli:
  o A Multicenter, Quasi-Experimental Study: Reducing Transmission of MDROs in Rehabilitation Centers
  o A Mathematical Model of Clostridium difficile Transmission in Medical Wards and a Cost-Effectiveness Analysis Comparing Different Strategies
     for Laboratory Diagnosis and Patient Isolation
  o Assessment of β-lactam/β-lactam Inhibitor (BL/BLI) combinations for the treatment of Bacteremia due to
     extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae: The INCREMENT project
  o Carbapenemase-Producing Enterobacteriaceae among Syrian Wounded Hospitalized in Northern Israel
  o Predictors of Carbapenem-resistant Enterobacteriaceae (CRE) Acquisition Following In-hospital Exposure to Newly Diagnosed CRE Patients
- Lena Friberg:
  o Optimal Design (OD) and In Vitro Validation of Reduced Time-Kill Curve Experiments for Pharmacokinetic-Pharmacodynamic (PKPD) modeling
  o A Whole-Body Physiologically Based Pharmacokinetic (WBPBPK) Model of Ciprofloxacin for Prediction of Bacterial Killing at the Site of Infection
  o Colistin (C) Pharmacokinetics (PK) after Application of a Loading Dose (LD) of 9 MU Colistin Methanesulfonate (CMS) in Critically Ill Patients
     Receiving Continuous Venovenous Hemodiafiltration (CVVHDF)
- William Hope:
  o PK-PD of Fosfomycin (FOS) Against ESBL-producing E. coli and KPC-3-producing K. pneumoniae
  o PK-PD of Vancomycin (VAN) Against S. epidermidis in a Hollow-Fiber Infection Model (HFIM)
  o Population Pharmacokinetics (PK) of Teicoplanin (TEI) in Children and Neonates

background logo AIDA-fine line


The 24th ECCMID will take place in Barcelona, Spain, May 10-13, 2014
Partners of AIDA will present at this meeting:

  • Johan Mouton: Basic concepts of PK/PD
    Value of the measurement of antibiotic concentration in tissues
  • Mical Paul: Clostridium difficile infection in the elderlyAminoglycosides used in combined treatment for multi-resistant Gram-negative bacteria
    Empirical therapy for MDR and XDR Gram-negatives

  • Stephan Harbarth: Challenges and solutions for development of new antibacterials: results of the Combacte opinion survey among pharmaceutical industry professionals
    Effectiveness of MDRO decolonisation: epidemiological and clinical determinants

  • Alasdair MacGowan: Pharmacokinetics and pharmacodynamics of nebulised antimicrobials, In treatment of Pseudomonas aeruginosa with piperacillin tazobactam, addition of low dose gentamicin markedly reduces emergence of resistance and increases antibacterial effect
  • Ursula Theuretzbacher: Optimising therapy to minimise emergence of resistance
    Developmental beta-lactamase inhibitors in phase 2/3 clinical trials
  • Yehuda Carmeli: Carbapenemases from (not) detection to control
    Beta-lactamase and breakpoints: do we have the right ones?

  • Leonard Leibovici: What are we trying to improve: long-term outcomes of sepsis
  • Laura Farbman: No association between colistin daily dose and clinical outcomes with low colistin dosing
    Is the efficacy of ertapenem reduced in the presence of severe hypoalbuminaemia?
  • Karen Bowker: Pre-clinical in vitro models
  • William Couet: Altered drug disposition in the elderly
    Microdialysis tissue pharmacokinetics and pharmacokinetic-pharmacodynamic modelling of ertapenem after 1g/12h administrations to critically ill patients

  • Niels Frimodt-Moller: Reintroducing pivmecillinam - Impact of resistance
    Pre-clinical in vivo models

ECCMID presentations related to the AIDA topics

background logo AIDA-fine line
ICAAC 2013
53rd ICAAC will take place in Denver, Colorado, USA, Sept. 10 - 13, 2013
Partners of AIDA will present at this meeting:

  • AR Noel, KE Bowker, S Tomaselli, AP MacGowan, WW Hope: Pharmacodynamics of minocycline against Staphylococcus aureus studied in an in vitro  pharmacokinetic model of infection.
  • Alasdair Macgowan: In Vitro Testing Challenges with the Polymyxins
  • Johan Mouton: Polymyxins: An Update
  • Johan Mouton: Pre-Clinical Models: What Have We Learned?
  • William Couet, Lena Friberg: Comparison of Colistin and Colistimethate sodium (CMS) Model-Predicted Whole Body Distribution with Measured Tissue:Plasma Concentrations Ratios in rats.

ICAAC Poster presentations - colistin, polymyxins
ICAAC Poster presentations - nitrofurantoin, fosfomycin trometamol, minocycline

background logo AIDA-fine line

1st International Conference on Polymyxins, 2 - 4 May, 2013, Monash Centre in Prato, Italy
!!! Presentations are now online !!!

This opinion-leader conference will feature state-of-the-art presentations by speakers who are world leaders in research and clinical use of polymyxins. Each symposium session will provide opportunity for discussion and input from the audience.

In addition, within each symposium key issues will be identified to go on the agenda for the final symposium of the conference, the Prato Polymyxin Consensus, in which recommendations will be made to guide the clinical use of polymyxins and identify high-priority areas for further research.
Preliminary program for the 1st International Conference on Polymyxins

Organizing Committee:
Roger Nation, Australia (Chair), Jian Li, Australia (Deputy Chair)
Otto Cars, Sweden; William Couet, France; Mike Dudley, USA; Bob Hancock, Canada; Johan Mouton, Netherlands; David Paterson, Australia; Vincent Tam, USA; Ursula Theuretzbacher, Austria; Brian Tsuji, USA; John Turnidge, Australia

Presentations of AIDA partners

William Couet: Pulmonary disposition of Polymyxins
Lena Fridberg: Importance of the loading dose: CMS vs polymyxin B    
Johan Mouton:

background logo AIDA-fine line

The 23rd European Congress of Clinical Microbiology and Infectious Diseases will be held in Berlin from 27 to 30 April 2013.
Presentations about colistin
Presentations about furantoin and fosfomycin trometamol
background logo AIDA-fine line

ICAAC 2012
The 52nd ICAAC will take place in San Francisco, USA, from 8th - 12th September.
Partners of AIDA will present at this meeting.

The first study of the AIDA project will be presented at ICAAC 2012 in San Francisco:
A. N. Kristoffersson, J. Nyberg, L. E. Friberg: Optimal Design of a Colistin Sparse Sampling Schedule for individual PK-parameter Estimation.ICAAC 2012.

Symposium: Targeting Gram-Negative Superbugs with Polymyxins: From Lab-Bench to Bedside

Presentations on colistin (see attachment)

For more information go to: http://www.icaac.org/
background logo AIDA-fine line


The 22nd ECCMID meeting will take place in London, UK from March 31 until April 3rd.
Partners of AIDA will present at this meeting.


Colistin use in clinical practice

Educational Workshop on Saturday, March 31, 2012, 11:00 - 13:00; Hall N11 B
Chair: M. Paul (Petah-Tiqva, IL), J.W. Mouton (Nijmegen, NL)
11:00 - 11:30 J.W. Mouton (Nijmegen, NL): Optimising use of old antibiotics: the PK/PD perspective
11:30 - 12:00 W. Couet (Poitiers, FR): Colistin PK/PD: lessons from recent studies
12:00 - 12:30 M. Paul, D. Yahav, L. Leibovici (Petah-Tikva, IL): Efficacy, use and dosing of colistin: what have contemporary studies taught us?
12:30 - 13:00 Y. Carmeli (Tel Aviv, IL): Synergy studies and combination treatment in clinical practice

For more information go to:  


Download this file (ICAAC 2012-colistin.doc)ICAAC 2012-colistin.doc[ICAAC 2012-presentations on colistin]757 kB